With an ever growing field of knowledge, target identification and drug development in oncology it is necessary to build strategic alliances between academic institutions and other important players including scientific organisations, international health agencies and pharmaceutical industry. Such alliances merge clinical experience, basic research expertise and modern biotechnology to guarantee successful drug development programs resulting in an improvement of cancer treatment options.
CCC-DTS is a translational research unit which speeds up the process of drug development and the design of effective cancer therapy in cooperation with important institutions engaging in the identification of treatment targets and the applicability of their function modulation in the clinic. CCC-DTS provides a drug testing platform, merges clinical data, genomics, proteomics and biomarkers to generate evidence-based surrogate endpoints which predict drug efficacy in oncology and hematology.
The platform is part of the Comprehensive Cancer Center (CCC) of the Medical University of Vienna and the General Hospital and is located within the Department of Medicine I. Its core facility operates in the tumor microenvironment laboratory within the Clinical Division of Hematology and Hemostaseology.
CCC-DTS possesses modern research infrastructure, a well trained research team, ex vivo models for drug testing and target validation and is connected to the microarray and proteomic units.
CCC-DTS has access to primary materials and tissue banks from patients with hematological malignancies and solid tumors, their clinical characteristics, genomics and proteomics and biomarkers to generate evidence-based surrogate endpoints which predict drug efficacy and accelerate drug development in oncology and hematology.